Promising Results for Izalontamab Brengitecan in Urothelial Cancer
Data from the phase 2 BL-B01D1-201 trial indicate that izalontamab brengitecan (also known as BL-B01D1) demonstrates significant efficacy in treating patients with locally advanced or metastatic urothelial carcinoma. The trial,…